Clinical trial · no report yet · Phase 2
NCT03612154
Study of Lorlatinib in ROS1 Rearranged NSCLC
- NCT03612154 ↗
- Unknown
- National Cancer Center, Korea
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Nonsmall Cell Lung Cancer
- Interventions
- Lorlatinib
- Arms
- Lorlatinib · Experimental
- Enrollment
- 35 (estimated)
- Primary outcomes
- ORR
- Sponsor
- National Cancer Center, Korea
- Start
- May 2, 2019
- Primary completion
- Dec 31, 2022 (estimated)
- Results posted
- No
- Registry record
- NCT03612154 · updated Apr 6, 2022
Publications
linked from the registry- Ahn BC, Kim YJ, Lee Y, Suh KJ, Kim SH, Kim DW, Kim TM, Lee KH, Han JY. Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2026 Jan 1;12(1):84-89. doi: 10.1001/jamaoncol.2025.5097. PubMed 41296331